Drug Trial Radar · NCT05445908
SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
184
Actual
Start
Aug 17, 2022
Primary completion
Jul 31, 2026
Study completion Jul 31, 2026
Sponsor
- Lead sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability and preliminary antitumor activity of SKB264 with/without KL-A167 in patients with unresectable locally advanced, recurrent or metastatic TNBC and HR+/HER2- BC .The study is divided into three parts.Part 1(TNBC): exploratory phase of the efficacy and safety of the combination treatment. Part 2(TNBC): The subjects will be randomized to treatment group for SKB264 + KL-A167 or SKB264 . Part 3(HR+/HER2- BC): The subjects will be randomized to treatment group for SKB264 + KL-A167 or SKB264 .
Conditions
- Triple-negative Breast Cancer and HR+/HER2- BC
Interventions
SKB264Drug
SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
KL-A167Drug
KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs)Time frame: From baseline up to 30 days after last dose or to the beginning of the new anti-cancer therapy, up to 24 months
- Objective Response Rate (ORR)Time frame: From baseline to first documented objective response, up to 24 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hunan Cancer Hospital
Changsha, Hunan, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.